Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of BRUIN (NCT03740529), a multicenter Phase I/II trial aiming to evaluate the efficacy and safety of LOXO-305, a highly selective BTK inhibitor, in patients with B-cell malignancies who have received more than 2 prior therapies. No dose-limiting toxicities were reported and treatment-related adverse events were scarce. The BRUIN trial shows that LOXO-305 has promising efficacy in previously treated MCL, WM as well as other non-Hodgkin lymphomas (NHL). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.